PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.43%
EBIT growth above 1.5x AGEN's 28.56%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-14.45%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
43.33%
Net income growth above 1.5x AGEN's 27.85%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
43.35%
EPS growth 1.25-1.5x AGEN's 32.04%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
43.35%
Diluted EPS growth 1.25-1.5x AGEN's 32.04%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.17%
Negative OCF growth while AGEN is at 131.36%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-15.15%
Negative FCF growth while AGEN is at 124.31%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-167027.54%
Negative 10Y OCF/share CAGR while AGEN stands at 139.48%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-35848.35%
Negative 5Y OCF/share CAGR while AGEN is at 354.50%. Joel Greenblatt would question the firm’s operational model or cost structure.
-39776.52%
Negative 3Y OCF/share CAGR while AGEN stands at 95.90%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-711192.96%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-12332.31%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-13057.95%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
90012.37%
10Y equity/share CAGR above 1.5x AGEN's 19.52%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5373.91%
5Y equity/share CAGR above 1.5x AGEN's 962.16%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
7310.97%
3Y equity/share CAGR above 1.5x AGEN's 2011.93%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Asset growth above 1.5x AGEN's 57.42%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
955.36%
BV/share growth above 1.5x AGEN's 89.46%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-33.08%
We’re deleveraging while AGEN stands at 90.86%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
0.44%
R&D dropping or stable vs. AGEN's 25.12%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
34.62%
SG&A growth well above AGEN's 2.10%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.